Peginterferon lambda-1a is a Recombinant Protein owned by Eiger BioPharmaceuticals, and is involved in 23 clinical trials, of which 17 were completed, 3 are ongoing, and 3 are planned.

PEG-Interferon lambda function by signaling through the JAK-STAT pathway upregulating the expression of genes involved in controlling viral replication and cellular proliferation. IFN-lambda shares with type I IFNs an intracellular signaling pathway that drives the expression of a common set of genes. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus. There they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation. The JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. JAK activation stimulates cell proliferation, differentiation, cell migration. Interferons are pleiotropic proteins, able to initiate and regulate a variety of responses, either directly or by stimulating the induction/activation of additional proteins.

The revenue for Peginterferon lambda-1a is expected to reach a total of $1.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Peginterferon lambda-1a NPV Report.

Peginterferon lambda-1a was originated by ZymoGenetics and is currently owned by Eiger BioPharmaceuticals.

Peginterferon lambda-1a Overview

Peginterferon lambda-1a is under development for the treatment of hepatitis delta virus infections and coronavirus disease 2019 (COVID-19). The drug candidate is administered by subcutaneous route. PEG-IFN lambda (BMS-914143) is a type III interferon. Interferons are a family of pleiotropic cytokines with antiviral, anti-proliferative and immuno-modulatory properties. The interferons targets membrane receptor (IFNAR). It was also under development for the treatment of hepatitis B and hepatitis C viral infection.

Eiger BioPharmaceuticals Overview

Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as lonafarnib and lambda which are used for the treatment of hepatitis delta virus infection; exendin 9-39 post-bariatric hypoglycemia; ubenimex for lymphedema and pulmonary arterial hypertension. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company also offers post-bariatric hypoglycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.

The company reported revenues of (US Dollars) US$12.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$76.9 million in FY2021, compared to an operating loss of US$62.2 million in FY2020. The net loss of the company was US$33.9 million in FY2021, compared to a net loss of US$65.1 million in FY2020. The company reported revenues of US$4 million for the third quarter ended September 2022, a decrease of 1.6% over the previous quarter.

Quick View – Peginterferon lambda-1a

Report Segments
  • Innovator
Drug Name
  • Peginterferon lambda-1a
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.